TLDR
- Repare’s stock drops 2.37% after XenoTherapeutics acquisition announcement.
- Repare shareholders to receive cash and contingent value rights in acquisition.
- XenoTherapeutics to acquire Repare, delisting shares from Nasdaq post-deal.
- Repare reports slight increase in cash, while clinical trials progress.
- Repare’s acquisition offers immediate cash and future royalties to investors.
Repare Therapeutics Inc. (Nasdaq: RPTX) saw its stock price drop by 2.37%, closing at $1.65.
Repare Therapeutics Inc., RPTX
This decline follows the announcement of a definitive agreement between Repare and XenoTherapeutics, Inc., a non-profit biotech company. The agreement will lead to Xeno acquiring all outstanding shares of Repare, triggering a cash payout and contingent value rights (CVRs) for shareholders.
XenoTherapeutics Acquisition Terms and Cash Payment
Repare shareholders will receive a cash payment of approximately $1.82 per share. This amount is based on Repare’s current estimated cash balance after deducting transaction costs and liabilities. Shareholders will also be entitled to non-transferable contingent value rights (CVRs), which provide future payments based on certain milestones.
These CVRs will entitle shareholders to 100% of certain receivables Repare may collect within 90 days following the closing. They will also receive a share of net proceeds from existing partnerships with companies like Bristol-Myers Squibb and Debiopharm. These payments will vary in percentage depending on the timing of the receipt, with the highest at 90% for the first two years post-closing.
Transaction Approval and Delisting Plans
The deal is subject to approval by Repare’s shareholders and the Superior Court of Québec. A special shareholder meeting will be held to vote on the transaction, requiring a two-thirds majority for approval. Upon completion, Repare will become a privately held company, and its shares will be delisted from Nasdaq, marking the end of its public trading.
Repare’s board has recommended the transaction after reviewing it with financial and legal advisors. They believe the deal offers value to shareholders through the immediate cash payment and potential future royalties. The company will also apply to deregister its shares in the United States and cease to be a reporting issuer under Canadian securities laws.
Financial Performance and Product Updates
For the third quarter of 2025, Repare reported a slight increase in cash and equivalents, totaling $112.6 million. The company’s revenue from collaboration agreements was $11.6 million for the quarter. Net research and development expenses decreased to $7.5 million, showing a reduction in costs compared to the same period last year.
Repare’s key drug candidates, including RP-1664 and RP-3467, are progressing through clinical trials. The company will no longer report topline data from the POLAR trial for its RP-3467 program. Despite the ongoing development of its pipeline, the acquisition by Xeno will now overshadow these efforts, redirecting Repare’s future towards private ownership and potential long-term payouts for shareholders.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
